Skip to content

Yoga for Patients With Epilepsy

Is Yoga Safe for Patients With Epilepsy?

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00179452
Enrollment
20
Registered
2005-09-16
Start date
2003-10-31
Completion date
2008-10-31
Last updated
2017-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epilepsy

Keywords

epilepsy, yoga

Brief summary

To establish the safety and feasibility of having patients with epilepsy perform yoga.

Detailed description

Subjects will keep logs of seizure frequency prior to, during, and following training in a yoga regimen. Instruction in the yoga regimen will occur at BIDMC, and home practice following classroom instruction will occur as part of the study. Side effects, changes in seizure frequency, and quality of life assessments will be performed.

Interventions

BEHAVIORALYoga

Sponsors

Beth Israel Deaconess Medical Center
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 64 Years
Healthy volunteers
No

Inclusion criteria

1. Must be able to give full informed consent. 2. Must have one or more of the following seizure types: simple partial, complex partial, or secondarily generalized. 3. Age 18-64. 4. Must have 4-20 during the baseline phase. 5. Must have medical clearance from their primary care giver sufficient to allow for participation in yoga exercises. 6. Must be stable enough to allow for all anticonvulsant levels to remain constant for the duration of the study.

Exclusion criteria

1. Having primary generalized epilepsy or atonic seizures. 2. Having a history of status epilepticus in the past two years. 3. Any medical problem that would preclude participation in a yoga class. 4. Nonepileptic or psychogenic seizures. 5. Pregnancy.

Design outcomes

Primary

MeasureTime frame
Improvement in quality of life assessments.3 months
Improvement in mood.3 months

Secondary

MeasureTime frame
Improvement in seizure control.3 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026